Monica Valeria Estrada

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2321050/publications.pdf

Version: 2024-02-01

27 papers	5,585 citations	236925 25 h-index	377865 34 g-index
34 all docs	34 docs citations	34 times ranked	10798 citing authors

#	Article	IF	Citations
1	Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PLoS ONE, 2016, 11, e0157368.	2.5	975
2	Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Medicine, 2019, 11, 34.	8.2	732
3	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Nonâ€“Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24,	4.3	530
4	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	4.3	469
5	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism, 2017, 26, 633-647.e7.	16.2	449
6	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research, 2016, 22, 1499-1509.	7.0	428
7	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nature Communications, 2016, 7, 10582.	12.8	412
8	A Phase Ib Study of Alpelisib (BYL719), a PI3KÎ±-Specific Inhibitor, with Letrozole in ER+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 26-34.	7.0	268
9	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Research, 2017, 77, 2488-2499.	0.9	178
10	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight, 2018, 3, .	5.0	128
11	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science Translational Medicine, 2016, 8, 334ra53.	12.4	105
12	A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clinical Cancer Research, 2017, 23, 4035-4045.	7.0	104
13	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine, 2017, 9, .	12.4	91
14	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. Science Translational Medicine, 2017, 9, .	12.4	89
15	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. Cancer Research, 2017, 77, 3280-3292.	0.9	76
16	Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Cancer Research, 2016, 76, 4752-4764.	0.9	71
17	Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2. Clinical Cancer Research, 2013, 19, 5390-5401.	7.0	67
18	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. Clinical Cancer Research, 2017, 23, 4323-4334.	7.0	64

#	Article	IF	Citations
19	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. Cancer Research, 2015, 75, 405-414.	0.9	53
20	USP11 Enhances TGFÎ²-Induced Epithelialâ€“Mesenchymal Plasticity and Human Breast Cancer Metastasis. Molecular Cancer Research, 2018, 16, 1172-1184.	3.4	41
21	Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Molecular Cancer Research, 2017, 15, 259-268.	3.4	40
22	LYN-activating mutations mediate antiestrogen resistance in estrogen receptorâ€“positive breast cancer. Journal of Clinical Investigation, 2014, 124, 5490-5502.	8.2	34
23	An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. Journal of the National Cancer Institute, 2017, 109, .	6.3	29
24	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research, 2018, 24, 2517-2529.	7.0	26
25	Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117065119.	7.1	26
26	Postâ€irradiation morphoea of the breast: a case report and review of the literature. Histopathology, 2018, 72, 342-350.	2.9	18
27	Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death and Disease, 2018, 9, 21.	6.3	16